Table 1.

Effect of GPIIb/IIIa + vβ3, GPIb, and GPIa/IIa Blockade on Thrombin Generation in PRP in the Presence and Absence of Fibrin Clots

Conditions Fibrin Clots No. ETP %PeakThrombin % PDMP % PMPA %Residual Factor II %
Control  −  16  100 100  100  100  12 ± 2  
 +  16 142 ± 4  164 ± 11 144 ± 7   178 ± 12  6 ± 1  
Anti-GPIIb/IIIa + αvβ3  −  10  42 ± 4   41 ± 4   44 ± 6    42 ± 3   32 ± 1 
 (7E3)  +  10   92 ± 6  89 ± 9    91 ± 6   72 ± 10  20 ± 2  
d-RGDW (60 μmol/L)  −  4  60  49  56  74  25 
 +  4  98  83  72  90  11 
Anti-GPIb  
 6D1  −  6   98 ± 7  95 ± 8    99 ± 11  97 ± 11  14 ± 2  
 +   85 ± 9   96 ± 14  92 ± 14   95 ± 15 12 ± 3  
 AP-1  −  3  101  94  100 104  13  
 +  3  97  97  95  98 14  
 CD42b  −  3  103  98  98  95 12  
 +  3  93  95  104  87 14  
Anti-GPIIb/IIIa + GPIb  −  3  46  59 49  37  32  
 (7E3 and 6D1)  +  3  51 57  55  40  30  
Anti-GPIa/IIa  −  105  100  98  104  11  
 (6F1)  +  135  171  148  150  
Anti-GPIIb/IIIa + Ia/IIa  −  3  58  55  49 47  26  
 (7E3 & 6F1)  +  3  90  89 101  73  19  
Ionomycin (10 μmol/L)  − 14  139 ± 4  145 ± 9  154 ± 14  147 ± 9   6 ± 1  
 (see legend)  +  14 136 ± 4  140 ± 10 144 ± 16  152 ± 9   6 ± 1 
Conditions Fibrin Clots No. ETP %PeakThrombin % PDMP % PMPA %Residual Factor II %
Control  −  16  100 100  100  100  12 ± 2  
 +  16 142 ± 4  164 ± 11 144 ± 7   178 ± 12  6 ± 1  
Anti-GPIIb/IIIa + αvβ3  −  10  42 ± 4   41 ± 4   44 ± 6    42 ± 3   32 ± 1 
 (7E3)  +  10   92 ± 6  89 ± 9    91 ± 6   72 ± 10  20 ± 2  
d-RGDW (60 μmol/L)  −  4  60  49  56  74  25 
 +  4  98  83  72  90  11 
Anti-GPIb  
 6D1  −  6   98 ± 7  95 ± 8    99 ± 11  97 ± 11  14 ± 2  
 +   85 ± 9   96 ± 14  92 ± 14   95 ± 15 12 ± 3  
 AP-1  −  3  101  94  100 104  13  
 +  3  97  97  95  98 14  
 CD42b  −  3  103  98  98  95 12  
 +  3  93  95  104  87 14  
Anti-GPIIb/IIIa + GPIb  −  3  46  59 49  37  32  
 (7E3 and 6D1)  +  3  51 57  55  40  30  
Anti-GPIa/IIa  −  105  100  98  104  11  
 (6F1)  +  135  171  148  150  
Anti-GPIIb/IIIa + Ia/IIa  −  3  58  55  49 47  26  
 (7E3 & 6F1)  +  3  90  89 101  73  19  
Ionomycin (10 μmol/L)  − 14  139 ± 4  145 ± 9  154 ± 14  147 ± 9   6 ± 1  
 (see legend)  +  14 136 ± 4  140 ± 10 144 ± 16  152 ± 9   6 ± 1 

The final concentration of each MoAb used was 20 μg/mL. d-RGDW was used at 60 μmol/L, ionomycin at 10 μmol/L. None of the antibodies had a measurable effect on thrombin generation in the presence of ionomycin, so all values were pooled in this case. Values are expressed as mean ± SEM and as a percentage of a normal control assayed concomitantly, except for the residual prothrombin content in the serum (last column), which is expressed as % of the original prothrombin content of the plasma. No SEM is given if n < 5; individual values were within 15% of the mean.

Abbreviations: ETP, endogenous thrombin potential; peak thrombin, highest thrombin concentration observed; PDMP, platelet derived, annexin V-positive microparticles; PMPA, platelet membrane-derived procoagulant phospholipid activity.

or Create an Account

Close Modal
Close Modal